The Lancet

Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease

aWallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Mölndal, Sweden bDepartment of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden ...
Taiwan News

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

NOVATO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...
Finanznachrichten

Ultragenyx Pharmaceutical Inc.: Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage ...

NOVATO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) ...
Mena FN

Ultragenyx Completes Rolling Submission Of Biologics License Application (BLA) To U.S. FDA For DTX401 AAV Gene Therapy For Glycogen Storage Disease Type Ia (Gsdia)

(MENAFN- GlobeNewsWire - Nasdaq) If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa NOVATO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx ...
Frontiers

The Unifying Hypothesis of Alzheimer’s Disease: Heparan Sulfate Proteoglycans/Glycosaminoglycans Are Key as First Hypothesized Over 30 Years Ago

The updated “Unifying Hypothesis of Alzheimer’s disease” (AD) is described that links all the observed neuropathology in AD brain (i.e., plaques, tangles, and cerebrovascular amyloid deposits), as ...